Higher dose of a lung cancer pill tested for tumors that spread to the brain
Original title: Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a small, early test in people at one hospital.
The short version
A small study tested a higher dose pill in people whose lung cancer had spread to the brain.
What was studied. Doctors gave 160 mg of firmonertinib once a day to twenty-three people. All had lung cancer with an EGFR gene change that had spread to the brain. All had already taken a similar pill that stopped working.
What they found. Brain tumors got smaller in 34.8% of people. In 91.3%, brain tumors got smaller or at least stopped growing. Side effects happened in 13 (56.5%) people, and most were mild.
What this means, and what it doesn't
What it could mean: For people in this spot, a higher dose of this pill may help hold back brain tumors. No one in the study had to stop the drug because of side effects. A doctor can say if this fits your own case.
What it doesn't mean: This was an early study at one hospital. Only twenty-three people took part, and there was no group to compare them to. Results like this often look different in bigger studies. It does not show this dose is better than other care. It is not a cure, and it is not everyday care today.
Source: PubMed, October 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.